GRI Bio (NASDAQ: GRI) shares new Phase 2a IPF trial data

Rhea-AI Filing Summary

GRI Bio, Inc. reported that it has issued a press release sharing additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis, a serious lung disease. The filing does not describe the details or outcomes of the new data, only that they were announced.

The company also noted that, following a public offering completed in December 2025, it believes its stockholders’ equity is now above the minimum $2.5 million requirement set by Nasdaq. This suggests the company currently expects to meet the exchange’s stockholders’ equity standard for continued listing.

Insights

Biotech and listing‑standards analyst

GRI Bio highlights new trial data disclosure and expected Nasdaq equity compliance.

GRI Bio points to a press release with additional data from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis. The filing confirms the existence of new clinical information but does not characterize the results, so the scientific or commercial implications of the data cannot be assessed from this text alone.

The company also states that, after a public offering completed in December 2025, it believes stockholders’ equity exceeds Nasdaq’s $2.5 million minimum. That language signals management’s current view that the equity listing standard is being met, which is important for maintaining trading on The Nasdaq Capital Market, though the precise equity level is not disclosed here.

FALSE000182429300018242932026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

GRI BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40034

82-4369909

(State or other jurisdiction

(Commission File Number)

(IRS Employer Identification No.)

of incorporation)

2223 Avenida de la Playa, #208

La Jolla, CA 92037

(Address of principal executive offices and zip code)

(619) 400-1170

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			GRI			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Press Release

On January 8, 2026, GRI Bio, Inc. (the “Company”) issued a press release announcing additional data from the Company’s Phase 2a clinical trial investigating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

Stockholders’ Equity

As a result of the Company’s public offering completed in December 2025 and as of the date of this Current Report on Form 8-K, the Company believes its stockholders’ equity is in excess of the minimum $2.5 million Nasdaq requirement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release issued by GRI Bio, Inc., dated January 8, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2026

GRI BIO, INC.

By:

/s/ Leanne Kelly

Name:

Leanne Kelly

Title:

Chief Financial Officer

FAQ

What did GRI Bio (GRI) disclose in this 8-K filing?

GRI Bio reported that it issued a press release with additional data from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis and stated that, after a December 2025 public offering, it believes stockholders’ equity exceeds Nasdaq’s $2.5 million minimum requirement.

What is the focus of GRI Bio (GRI)'s Phase 2a clinical trial?

The Phase 2a clinical trial is investigating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis, a chronic and progressive lung disease.

Did GRI Bio describe the Phase 2a trial results in this 8-K?

No. The filing only states that a press release was issued announcing additional data from the Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis; it does not describe the specific results or outcomes.

How does this filing relate to GRI Bio (GRI)'s Nasdaq listing requirements?

GRI Bio states that, as a result of a public offering completed in December 2025, it believes its stockholders’ equity is above the Nasdaq minimum of $2.5 million, which is one of the requirements for continued listing on The Nasdaq Capital Market.

What corporate event helped GRI Bio (GRI) meet the Nasdaq equity threshold?

The company cites its public offering completed in December 2025 as the reason it believes stockholders’ equity now exceeds the Nasdaq $2.5 million minimum standard.

Where can investors find the detailed trial data mentioned by GRI Bio (GRI)?

The detailed additional data from the Phase 2a GRI-0621 trial are contained in the press release dated January 8, 2026, which is referenced in the filing and attached as Exhibit 99.1.